27 September 2023
DEP® irinotecan combination data presentation
27 September 2023
DEP® irinotecan combination data to be presented at international oncology conference
25 September 2023
VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment
20 September 2023
Change in substantial holding
13 September 2023
Positive DEP® irinotecan clinical results to be presented at international oncology conference
12 September 2023
Change in substantial holding
28 August 2023
Change of Company Secretary
24 August 2023
Appendix 4G – Corporate Governance Statement
24 August 2023
Starpharma annual report and full-year financial results
17 August 2023
Change in substantial holding
15 August 2023
Change in substantial holding
14 August 2023
Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV
2 August 2023
Change in substantial holding
31 July 2023
Quarterly Activities Report & Appendix 4C
31 July 2023
Partnered program update
28 July 2023
Trading Halt Announcement - Partnered Program
26 July 2023
Starpharma partners with UQ to advance DEP® radio pipeline
21 July 2023
DEP® HER2-radiodiagnostic shows imaging benefits
27 June 2023
Clinical trial update
23 June 2023
Life Sciences Investor Presentation

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.